AU2015317330B2 - Methods for treating brain metastasis - Google Patents

Methods for treating brain metastasis Download PDF

Info

Publication number
AU2015317330B2
AU2015317330B2 AU2015317330A AU2015317330A AU2015317330B2 AU 2015317330 B2 AU2015317330 B2 AU 2015317330B2 AU 2015317330 A AU2015317330 A AU 2015317330A AU 2015317330 A AU2015317330 A AU 2015317330A AU 2015317330 B2 AU2015317330 B2 AU 2015317330B2
Authority
AU
Australia
Prior art keywords
cancer
inhibitor
subject
brain
gap junction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015317330A
Other languages
English (en)
Other versions
AU2015317330A1 (en
Inventor
Adrienne BOIRE
Qing Chen
Joan Massague
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2015317330A1 publication Critical patent/AU2015317330A1/en
Application granted granted Critical
Publication of AU2015317330B2 publication Critical patent/AU2015317330B2/en
Priority to AU2021202257A priority Critical patent/AU2021202257B2/en
Priority to AU2023219864A priority patent/AU2023219864A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
AU2015317330A 2014-09-19 2015-09-18 Methods for treating brain metastasis Active AU2015317330B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021202257A AU2021202257B2 (en) 2014-09-19 2021-04-14 Methods for treating brain metastasis
AU2023219864A AU2023219864A1 (en) 2014-09-19 2023-08-23 Methods for treating brain metastasis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052966P 2014-09-19 2014-09-19
US62/052,966 2014-09-19
PCT/US2015/051057 WO2016044790A1 (en) 2014-09-19 2015-09-18 Methods for treating brain metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202257A Division AU2021202257B2 (en) 2014-09-19 2021-04-14 Methods for treating brain metastasis

Publications (2)

Publication Number Publication Date
AU2015317330A1 AU2015317330A1 (en) 2017-04-13
AU2015317330B2 true AU2015317330B2 (en) 2021-01-14

Family

ID=55533931

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015317330A Active AU2015317330B2 (en) 2014-09-19 2015-09-18 Methods for treating brain metastasis
AU2021202257A Active AU2021202257B2 (en) 2014-09-19 2021-04-14 Methods for treating brain metastasis
AU2023219864A Abandoned AU2023219864A1 (en) 2014-09-19 2023-08-23 Methods for treating brain metastasis

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021202257A Active AU2021202257B2 (en) 2014-09-19 2021-04-14 Methods for treating brain metastasis
AU2023219864A Abandoned AU2023219864A1 (en) 2014-09-19 2023-08-23 Methods for treating brain metastasis

Country Status (7)

Country Link
US (3) US10413522B2 (OSRAM)
EP (2) EP3685832B1 (OSRAM)
JP (1) JP6898848B2 (OSRAM)
CN (1) CN107106544B (OSRAM)
AU (3) AU2015317330B2 (OSRAM)
CA (1) CA2961894C (OSRAM)
WO (1) WO2016044790A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106544B (zh) * 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法
CN107290438B (zh) * 2016-03-31 2020-10-16 深圳翰宇药业股份有限公司 一种多肽有关物质的高效液相色谱分析方法
KR20200037796A (ko) * 2017-07-10 2020-04-09 코넬 유니버시티 암 치료를 위한 염색체 불안정성 및 다운스트림 사이토졸 dna 시그널링의 표적화
CA3072087A1 (en) * 2017-08-11 2019-02-14 Board Of Regents, The University Of Texas System Targeting kinases for the treatment of cancer metastasis
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
US20220401408A1 (en) * 2019-09-13 2022-12-22 Auckland Uniservices Limited Compositions and methods for rescuing retinal and choroidal structure and function
CN111420025B (zh) * 2020-04-28 2021-06-11 中国药科大学 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
GB202014831D0 (en) 2020-09-21 2020-11-04 Dc Europa Ltd Disconnection agents
US12306192B2 (en) * 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
CN114252324B (zh) * 2022-03-02 2022-05-13 中国人民解放军军事科学院军事医学研究院 一种方便使用的多孔脑片孵育装置
WO2024020491A1 (en) * 2022-07-20 2024-01-25 The University Of North Carolina At Chapel Hill Methods of treating cancer of the central nervous system comprising 5-ethynyl-2'-deoxyuridine
WO2025024284A1 (en) * 2023-07-21 2025-01-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against pcdh7 for lung cancer therapy
CN117298143A (zh) * 2023-10-11 2023-12-29 广州医科大学附属第一医院（广州呼吸中心） β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69518322T2 (de) 1994-06-10 2001-02-15 Smithkline Beecham P.L.C., Brentford C-4 amid substituierte verbindungen und deren verwendung als therapeutische mittel
GB9411635D0 (en) 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment
DE69833791D1 (de) 1997-11-24 2006-05-04 Scripps Research Inst Hemmer der "gap junction communication"
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6251931B1 (en) 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6770633B1 (en) 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US20060058379A1 (en) 2002-11-29 2006-03-16 Yasuyuki Kita Connexin 26 inhibitor and cancer metastasis inhibitors
CN1852721B (zh) * 2003-07-31 2013-03-27 得克萨斯大学体系董事会 用于治疗、预防和/或改善癌症、癌症发病或癌症症状的组合物和方法
KR20150004906A (ko) 2005-02-03 2015-01-13 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
WO2008127251A1 (en) 2006-05-05 2008-10-23 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Reversible inhibition of pyramidal gap junction activity
AU2008343755A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars
US20130281524A1 (en) * 2008-06-05 2013-10-24 Peter Blower Novel treatments
JP2012510953A (ja) * 2008-08-27 2012-05-17 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク 毒性を減少し、そして疾病を治療又は予防するための化合物、組成物及び方法
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20110262442A1 (en) * 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
CA2782631A1 (en) 2009-12-03 2011-06-09 Proximagen Ltd Treatment of infectious diseases
JP2013512887A (ja) * 2009-12-03 2013-04-18 プロキシマゲン リミテッド 感染症の治療
CA2908154C (en) * 2013-04-29 2023-11-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2015057862A1 (en) * 2013-10-15 2015-04-23 President And Fellows Of Harvard College Methods and compositions for eradicating leukemic cells
CN107106544B (zh) * 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Li, X et al (2012) Journal of Cancer Therapy 3: 64-70 *
Soranio-Hernandez, AD et al (2011) Int Urol Nephrol 44:471-477 *

Also Published As

Publication number Publication date
US11058665B2 (en) 2021-07-13
AU2015317330A1 (en) 2017-04-13
US20220105069A1 (en) 2022-04-07
AU2023219864A1 (en) 2023-09-14
CN107106544B (zh) 2021-09-24
EP3685832A1 (en) 2020-07-29
US20200085781A1 (en) 2020-03-19
EP3193865A1 (en) 2017-07-26
EP3685832B1 (en) 2023-08-30
US12029717B2 (en) 2024-07-09
CA2961894C (en) 2023-12-12
JP2017534583A (ja) 2017-11-24
WO2016044790A1 (en) 2016-03-24
EP3193865B1 (en) 2019-11-06
EP3193865A4 (en) 2018-04-11
AU2021202257A1 (en) 2021-05-06
US10413522B2 (en) 2019-09-17
US20170258758A1 (en) 2017-09-14
AU2021202257B2 (en) 2023-05-25
CA2961894A1 (en) 2016-03-24
CN107106544A (zh) 2017-08-29
NZ730319A (en) 2024-03-22
JP6898848B2 (ja) 2021-07-07

Similar Documents

Publication Publication Date Title
AU2021202257B2 (en) Methods for treating brain metastasis
Chen et al. Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer
Hua et al. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition
Hayes et al. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas
Zhan et al. Ovarian cancer stem cells: a new target for cancer therapy
Luo et al. Breast cancer stem cells: current advances and clinical implications
Spivak-Kroizman et al. Hypoxia triggers hedgehog-mediated tumor–stromal interactions in pancreatic cancer
Huetz et al. Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells
Wang et al. Hsa_circ_0128846 promotes tumorigenesis of colorectal cancer by sponging hsa‐miR‐1184 and releasing AJUBA and inactivating Hippo/YAP signalling
Gibellini et al. LonP1 differently modulates mitochondrial function and bioenergetics of primary versus metastatic colon cancer cells
US9493775B2 (en) Inhibition of the glycine cleavage system for treatment of cancer
Zheng et al. PTK6 activation at the membrane regulates epithelial–mesenchymal transition in prostate cancer
Hu et al. Inhibition of Pten deficient castration resistant prostate cancer by targeting of the SET-PP2A signaling axis
Pajuelo-Lozano et al. Targeting MAD2 modulates stemness and tumorigenesis in human Gastric Cancer cell lines
Subramani et al. The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis
Andugulapati et al. AMP-activated protein kinase promotes breast cancer stemness and drug resistance
CN103648505B (zh) 与微rna-21、错配修复和结肠直肠癌相关的材料和方法
López-Moncada et al. Secreted protein acidic and rich in cysteine (SPARC) induces epithelial-mesenchymal transition, enhancing migration and invasion, and is associated with high Gleason score in prostate cancer
Decaudin et al. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy
Tse et al. Activation of Wnt signaling pathway by AF1q enriches stem-like population and enhance mammosphere formation of breast cells
Sun et al. circTOP2A functions as a ceRNA to promote glioma progression by upregulating RPN2
Shigeishi et al. PGE2 targets squamous cell carcinoma cell with the activated epidermal growth factor receptor family for survival against 5-fluorouracil through NR4A2 induction
Gu et al. CLASRP oncogene as a novel target for colorectal cancer
Li et al. USP28 knockdown and small molecule inhibitors promote KRT1 destabilization and sensitize hepatocellular carcinoma cells to sorafenib
Sun et al. SPC25 upregulates CCND1 to promote the progression of esophageal squamous cell carcinoma by MDM2-mediated E2F1 ubiquitination and stabilization

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)